If you are looking into psychedelic-assisted treatment in Cyprus (for yourself or for someone close to you), the honest summary for July 2026 is short: we found no public-system route, and one private route we could verify. A specialised neuromodulation centre in Nicosia offers ketamine treatment for depression alongside rTMS, run by clinicians who publish on their own patient outcomes. Psilocybin and MDMA are research-only. This guide covers what the route involves, how to start, and, unusually much for this series, what we could not confirm; you can begin orienting yourself with our eligibility check.
A note on scope: this guide covers medical ketamine and esketamine therapy for depression, licensed depression treatment, not addiction rehabilitation services.
TL;DR We could not find any GESY decision or listing covering esketamine or ketamine treatment for depression in Cyprus, so treat the public route as unconfirmed. The route that works is private: the Cyprus rTMS centre in Nicosia, directed by psychiatrist Dr George Mikellides, offers intramuscular ketamine for treatment-resistant depression (typically six to eight injections over three to four weeks, each session about 40–45 minutes), and has published peer-reviewed research comparing ketamine with rTMS in its own patients. Prices are not published; contact the clinic for a written quote. Psilocybin and MDMA remain research-only.
At a glance
| Route | Substance | Status in Cyprus | Who qualifies | Cost |
|---|---|---|---|---|
| Private ketamine | Ketamine (IM, off-label) | Legal; offered at the Cyprus rTMS centre in Nicosia | Clinic screening: treatment-resistant depression and related conditions | Not published; ask for a written quote |
| GESY-covered esketamine | Esketamine (Spravato) | Not confirmed: no coverage decision found | – | – |
| Psilocybin therapy | Psilocybin | Research only | – | – |
| MDMA therapy | MDMA | Research only | – | – |
| Clinical trials | Psilocybin, MDMA, ketamine | No Cypriot site in our tracked registry data | Study-specific criteria | Free |
How Cyprus compares across the continent: Europe-wide reimbursement map.
The public system: nothing we could confirm
Cyprus's General Healthcare System (GESY) covers a broad medicines catalogue, but we could not find any published GESY listing, tender or decision covering esketamine (Spravato) or ketamine treatment for depression, nor any state hospital advertising such a service. That is not proof of absence: it is an unverified gap, and we say so plainly. If public coverage matters to your decision, ask a GESY psychiatrist directly whether esketamine can be prescribed and funded in your case, and treat any answer you get as worth documenting. For how esketamine coverage works where it does exist, see our Europe-wide reimbursement map.
Private ketamine at the Cyprus rTMS centre
The one provider we have verified is the Cyprus rTMS centre in Nicosia, a private clinic specialising in treatment-resistant depression, directed by psychiatrist Dr George Mikellides, Clinical Assistant Professor of Psychiatry at the University of Nicosia Medical School. Alongside repetitive transcranial magnetic stimulation, the centre offers ketamine treatment given as intramuscular injections: a full course is typically six to eight injections over three to four weeks, with each treatment session lasting about 40–45 minutes; short-term side effects such as nausea and fatigue usually settle quickly (Famagusta News).
What sets the centre apart in this region is that its clinicians publish: a study of 24 treatment-resistant depression patients treated at the centre, comparing ketamine with rTMS, appeared in Frontiers in Psychiatry and found significant symptom improvement in both groups with no significant difference between them (Mikellides et al., 2021). That is a small retrospective sample, not a verdict on which treatment is better, but it means the clinic's claims can be checked against its own published data, which is rare.
How to start and what it costs. Ketamine here is used off-label, which is legal and standard practice; admission follows the clinic's own psychiatric screening, and you can self-refer by contacting the centre. Prices are not published; ask for a written cost breakdown for the full course, including assessment and follow-up, before starting. To see what is listed for Cyprus, browse providers in Cyprus.
What we don't know yet
An honest list of the gaps in our verification, as of 30 July 2026:
- GESY status. We found no coverage decision for esketamine or ketamine either way, unconfirmed, not confirmed-negative.
- Whether Spravato is available at all in Cyprus. We could not verify pharmacy distribution of the branded spray or any clinic offering it.
- Prices. The Cyprus rTMS centre does not publish ketamine pricing; we have no verified figures.
- Other providers. One verified clinic does not mean only one exists: private psychiatric clinics in Limassol or Larnaca may offer ketamine without publishing it.
Psilocybin and MDMA: research only
Psilocybin and MDMA remain controlled substances in Cyprus with no medical-access route (Psychedelic Alpha tracker), and our tracked registry data shows no Cypriot psychedelic trial site. The realistic option is a trial elsewhere in Europe: our trials guide explains how to search. Anyone offering psilocybin or MDMA therapy commercially in Cyprus today is operating illegally.
What to expect in treatment
Medically reviewed by Dr. Amy Reichelt, PhD, 31 July 2026: this section and the risks section below.
These routes share a shape (medical screening, supervised administration, structured follow-up), but they are not interchangeable: the indication, the schedule, the staffing and the strength of the evidence all differ depending on whether you are prescribed Spravato (esketamine), given ketamine, or entering a legal psychedelic-assisted therapy route, where your country has one. What every route has in common is where it starts. Treatment begins with a screening appointment: the clinician reviews your psychiatric and medication history, checks your cardiovascular health and current medicines, and confirms the diagnosis before anything is scheduled. This is also where contraindications are caught.
On a Spravato day you self-administer the nasal spray in the practice or clinic under supervision, then stay for an observation period of roughly two hours while staff monitor blood pressure, heart rate, sedation, dissociation, breathing and overall recovery. Dissociation, dizziness, sedation, nausea and a temporary rise in blood pressure are common (though they do not occur in everyone), and settle as the drug clears. You must not drive, operate machinery or undertake anything hazardous until the following day, after a night's sleep, so arrange transport home. Induction is typically more frequent at first and then tapers based on measured response. Under the European label, Spravato for treatment-resistant depression is taken alongside a continuing oral SSRI or SNRI antidepressant.
A ketamine infusion for depression is an off-label use of the drug. It is usually given intravenously over about 40 minutes, with vital-sign and psychological monitoring and a recovery period afterwards. Some services offer ketamine-assisted psychotherapy (KAP), which wraps the dosing in preparation and integration sessions with a therapist; others provide ketamine as a medical antidepressant treatment with no psychotherapy component at all, which is worth establishing before you book. Where a legal psychedelic-assisted therapy route exists, and what that route is depends on the country: a clinical trial in most, a regulated programme or compassionate-use scheme in a few; dosing days are long and closely supervised by trained clinical staff, and sit inside a broader plan of preparation, general psychiatric care and integration. In every setting the medicine is one part of the plan: screening, monitoring and follow-up reduce risk but cannot eliminate it, and psychotherapy or integration may help you make sense of what the treatment brings up and apply it afterwards.
Risks and who should not start
These treatments are generally well tolerated under supervision, but they are not for everyone, which is exactly what screening is for. Common, transient effects during or shortly after a session include dissociation (a detached, dreamlike feeling), nausea, mild perceptual changes, and a short-lived rise in blood pressure and heart rate; these resolve as the drug is metabolised. Treatment may be inappropriate, or require particular caution and specialist evaluation, when any of the following apply:
- Uncontrolled hypertension or significant cardiovascular instability, including a history of aneurysmal vascular disease. This is a contraindication for Spravato, because of the temporary rise in blood pressure; the other treatments carry their own cardiovascular assessment.
- A personal or family history of psychosis or bipolar disorder: a particular caution for classic psychedelics such as psilocybin, which legal programmes screen for carefully.
- Pregnancy or breastfeeding.
- Current uncontrolled substance use, a history of ketamine misuse, or a high risk of compulsive use: any of these may make treatment inappropriate or require specialist assessment.
A responsible provider screens for all of these before the first dose. Careful screening, monitoring and follow-up reduce risk; they do not remove it. If a clinic is willing to treat you without that assessment, treat it as a warning sign; see our clinic-choice guide. To see who is listed near you, browse providers in Cyprus.
Reviewer's note. Ketamine, Spravato (esketamine) and psilocybin-assisted therapies share common elements such as screening, supervision and follow-up, but they should not be presented as interchangeable. Each has distinct indications, contraindications, monitoring requirements and levels of evidence. Spravato follows a regulated treatment pathway, while IV ketamine is generally used off-label and psilocybin therapies remain largely investigational. Importantly, careful screening and clinical monitoring reduce risk but do not eliminate it.
— Dr. Amy Reichelt, PhD, neuroscientist, chartered psychologist and psychotherapist, PsyAccess medical reviewers
Frequently asked questions
Does GESY cover ketamine or esketamine treatment?
We could not confirm any coverage. No published GESY listing or decision was found, which leaves the status genuinely unknown; ask a GESY psychiatrist directly, and let us know what you learn.
What does ketamine treatment at the Cyprus rTMS centre involve?
Intramuscular ketamine injections after psychiatric screening: a full course is typically six to eight injections over three to four weeks, each session around 40–45 minutes including observation. The centre combines this with its neuromodulation practice and has published outcome data on its own patients.
How much does it cost?
Prices are not published. Request a written quote for the complete course (screening, injections, monitoring and follow-up) before committing, and compare with figures elsewhere in our cost guide.
Can I get psilocybin or MDMA therapy in Cyprus?
No. Both are research-only, no Cypriot trial is in our tracked data, and no legal clinical route exists. Watch the registries or consider trial sites elsewhere in Europe.
Coming from another country? Whether a clinic will take a non-resident self-pay patient, what a Spravato induction schedule means for a visitor, and where cross-border treatment actually works: ketamine & psychedelic therapy in Europe for international patients.
Sources
- Cyprus rTMS centre — Nicosia
- Cyprus rTMS centre: Ketamine treatment
- Famagusta News: Pioneering research on depression in Cyprus — ketamine vs rTMS study details
- Mikellides et al., Frontiers in Psychiatry (2021): Comparison of ketamine and rTMS in treatment-resistant depression
- GESY — General Healthcare System of Cyprus
- EMA: Spravato (esketamine) EPAR
- Psychedelic Alpha: Worldwide psychedelic laws tracker
- ClinicalTrials.gov
This guide is for general information only and is not medical advice, a diagnosis, or a recommendation of any treatment. Regulations, prices and coverage rules can change; always verify current requirements with the Health Insurance Organisation (GESY), the clinic, or a licensed clinician who knows your history. If you are in crisis, contact your local emergency number or a crisis line immediately.
This guide awaits review by a licensed medical professional.